In this episode of The HemOnc Pulse, Dr. Omar Nadeem of Dana-Farber Cancer Institute discusses how genomic data are reshaping the understanding of smoldering myeloma. He explains why traditional risk models may fall short and how molecular insights could guide earlier, more precise intervention. “We’re really left with more disease-burden-based risk stratification tools,” Dr. Nadeem notes, “but not necessarily any of the genomic data that tell us what’s happening underneath the hood.”